News - Johnson & Johnson, Markets & Marketing

Filter

Popular Filters

1 to 25 of 49 results

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

Topamax safety concerns as a treatment for migraines in adolescents, despite recent FDA approval

11-04-2014

The US Food and Drug Administration’s recent approval of Johnson & Johnson subsidiary Janssen’s Topamax…

JanssenJohnson & JohnsonMarkets & MarketingNeurologicalPharmaceuticalRegulationTopamax

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

NICE consults on draft guidance backing Invokana, as drug debuts in the UK

24-02-2014

UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

Strong pipeline of MAbs biosimilars in the USA and Europe lends impetus to global market

30-01-2014

The imminent entry of several companies, including big pharma, small biotech and generic participants,…

BioconBiosimilarsCellTrionDr Reddy's LaboratoriesEuropeHospiraJohnson & JohnsonMarkets & MarketingNorth AmericaRemicadeUSA

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

05-11-2013

Global health care giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve…

FinancialInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalScios

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

11-10-2013

Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Improved symptom control and quality of life among greatest unmet needs in metastatic-resistant prostate cancer therapy

06-06-2013

Symptom control and quality of life is one of the factors the most influences surveyed US and European…

BayerCometriqEuropeExelixisJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyorteronelPharmaceuticalTakeda PharmaceuticalsXofigoZytiga

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

European Commission enforcement action in pharmaceutical sector following sector inquiry

31-01-2013

Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Pharmstandard to produce Janssen's anti-TB drugs in Russia; Nyuvak deal

24-01-2013

JSC Pharmstandard (PHST: MM), one of Russia's largest pharmaceutical producers, has signed an agreement…

Antibiotics and Infectious diseasesbedaquilineEuropeJanssenJohnson & JohnsonMarkets & MarketingNyuvakOncologyPharmaceuticalPharmstandardProductionquisinostat

First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe

20-12-2012

For the treatment of hepatitis C virus (HCV), the elimination of interferons (IFNs) from regimens is…

Anti-viralsBiotechnologyEuropeIncivekIncivoJohnson & JohnsonMarkets & MarketingMitsubishi TanabeNorth AmericaPharmaceuticalRocheTelavicVertexVictrelis

Pain therapies sales to exceed $49 billion in 2026, driven by new product launches

16-12-2012

The market for pain therapies will grow at an annual rate of 1.8% over the next 15 years, surpassing…

BiotechnologyfulranumabGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalTakeda Pharmaceuticalstanezumabtapentadol

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

1 to 25 of 49 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top